Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

January 15, 2026
Pharmidex offers a broad range of pre-clinical respiratory disease models to support drug discovery and development across multiple pulmonary indications. Our capabilities include validated models for asthma (acute, chronic and severe/exacerbation), cough, idiopathic pulmonary fibrosis (IPF), acute lung injury/ARDS, respiratory infections, COPD and allergic rhinitis. These models incorporate clinically relevant triggers and well-established positive controls, enabling robust and translational assessment of novel therapeutics. Our integrated respiratory platforms are designed to help accelerate informed decision-making from early research through to advanced pre-clinical development. If you are developing new therapies for respiratory diseases, we would be pleased to discuss how Pharmidex can support your programme. ๐ŸŒ www.pharmidex.com
January 14, 2026
At Pharmidex , we offer In Vivo (Non-GLP & GLP), In Vitro, and Organ-on-Chip toxicology, alongside our full range of non-GLP and GLP toxicology studies delivered in the UK, with quick turnaround times and UK-competitive pricing. Our experienced team supports your programme from study design through delivery, helping you generate high-quality, decision-ready data efficiently and cost-effectively. ๐Ÿ“ UK-based studies โšก Rapid timelines ๐Ÿ’ท Competitive pricing ๐Ÿงช In Vivo (Non-GLP & GLP), In Vitro & Organ-on-Chip toxicology Learn more: www.pharmidex.com
January 8, 2026
We’re pleased to share that Martin Barrett from Pharmidex will be attending the R SC-BMCS Postgraduate Symposium XIX – Biological and Medicinal Chemistry Symposium for Postgraduates. ๐Ÿ“… Thursday 8th January 2026 ๐Ÿ“ MIB Building, Manchester Martin will be presenting at the symposium and representing Pharmidex to discuss our services and capabilities in drug discovery and development. He would be delighted to meet and chat with attendees, explore new ideas, and discuss potential collaborations and partnerships. If you’re attending, please come and say hello! ๐ŸŒ www.pharmidex.com ๐Ÿ”— https://www.rscbmcs.org/events/psxix/
More Posts